Recent Updates — TLX

Telix Pharmaceuticals reported third-quarter revenue of US$245 million, a 19% increase year-over-year, driven by strong demand for its commercial portfolio. The company also announced a transformative merger with Isotope Technologies Munich SE (ITM), involving upfront consideration of US$1.65 billion and contingent payments up to US$700 million. Additionally, Telix received FDA approval for Pixclara for glioma imaging and revised its full-year R&D expenditure guidance to US$240–260 million. Telix Pharmaceuticals is a commercial-stage global radiopharmaceutical company advancing targeted theranostics for cancer treatment.

Telix Pharmaceuticals Limited reported half-year 2026 results ending June 30, 2026, with revenue increasing 22% to $477 million and net profit turning positive at $38.3 million compared to a loss of $2.3 million in the prior year period. The company received a $40 million upfront payment from Regeneron Pharmaceuticals for a strategic collaboration on next-generation radiopharmaceutical therapies. Precision Medicine revenue grew 27% to $388 million, driven by Illuccix and Gozellix sales, while Telix Manufacturing Solutions generated $89 million in third-party revenue. The company reaffirmed its full-year FY2026 revenue guidance of $950 million to $970 million. Telix Pharmaceuticals Limited operates in the biopharmaceutical industry, developing and commercializing targeted radiopharmaceuticals for cancer diagnosis and treatment.

Telix Pharmaceuticals Limited announced alignment with the FDA to advance its ProstACT Global Phase 3 clinical trial. The company filed an announcement with the Australian Securities Exchange on July 2, 2026, regarding this regulatory progress. Telix Pharmaceuticals is a radiopharmaceutical company focused on developing diagnostic and therapeutic solutions.